A Phase I, Open-label, Non-randomised Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of a Single Oral Dose of AZD9291 in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI

Trial Profile

A Phase I, Open-label, Non-randomised Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of a Single Oral Dose of AZD9291 in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Osimertinib (Primary) ; Itraconazole
  • Indications Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 11 Jul 2016 Planned End Date changed from 1 May 2016 to 1 Jan 2018.
    • 11 Jul 2016 Status changed from completed to active, no longer recruiting.
    • 07 Jun 2016 Results from this trial and other trial (NCT02197247) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top